CD29 is a member of the family of integrins, membrane receptors involved in cell adhesion and recognition in a variety of processes including embryogenesis, hemostasis, tissue repair, immune response and metastatic diffusion of tumor cells.
| Inventor | Institute |
|---|---|
| Martin Humphries | University of Manchester |
| Cat. #: | 152482 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Cell signaling and signal transduction;Genetics;Immunology |
| Application: | ELISA ; FACS ; IHC ; IF ; IP ; WB |
| Target: | CD29 (Integrin b1 chain) |
| Reactivity: | Human |
| Clone: | 12G10 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Integrin Subunit Beta 1; Glycoprotein Iia; MSK12; GPIIA; FNRB; MDF2; Very Late Activation Protein; Beta Polypeptide; Fibronectin Receptor Subunit Beta; Integrin VLA-4 Beta Subunit; CD29 Antigen; VLA-BETA; CD29; VLAB |
|---|---|
| Product description: | CD29 is a member of the family of integrins, membrane receptors involved in cell adhesion and recognition in a variety of processes including embryogenesis, hemostasis, tissue repair, immune response and metastatic diffusion of tumor cells. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Purified human ?1 integrin preparation from HT1080 fibrosarcoma cell extract. |
| Myeloma used: | P3X63Ag8.653 |
| Target background: | CD29 is a member of the family of integrins, membrane receptors involved in cell adhesion and recognition in a variety of processes including embryogenesis, hemostasis, tissue repair, immune response and metastatic diffusion of tumor cells. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Chen et al. 2009. PLoS One. 4(8):e6565. PMID: 19668337. MMP7 shedding of syndecan-1 facilitates re-epithelialization by affecting alpha(2)beta(1) integrin activation. Yamamoto et al. 2009. Endocrinology. 150(2):990-9. PMID: 18845630. N-acetylglucosaminyltransferase V regulates extravillous trophoblast invasion through glycosylation of alpha5beta1 integrin. Yamamoto et al. 2007. Br J Cancer. 97(11):1538-44. PMID: 17971775. Expression of N-acetylglucosaminyltransferase V in endometrial cancer correlates with poor prognosis. Cavallo-Medved et al. 2005. J Cell Sci. 118(Pt 7):1493-503. PMID: 15769846. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. Avizienyte et al. 2002. Nat Cell Biol. 4(8):632-8. PMID: 12134161. Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Iba et al. 2000. J Cell Biol. 149(5):1143-56. PMID: 10831617. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. Mould et al. 1998. Biochem J. 331 ( Pt 3):821-8. PMID: 9560310. Regulation of integrin function: evidence that bivalent-cation-induced conformational changes lead to the unmasking of ligand-binding sites within integrin alpha5 beta1. Mould et al. 1995. Biochem Soc Trans. 23(3):395S. PMID: 8566283. Regulation of integrin alpha 5 beta 1 function by anti-integrin antibodies and divalent cations. Mould et al. 1995. FEBS Lett. 363(1-2):118-22. PMID: 7537221. Identification of a novel anti-integrin monoclonal antibody that recognises a ligand-induced binding site epitope on the beta 1 subunit. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.